Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q3 2024 · 10-Q
Revenue$213.30M$213.30M+11.2% vs Q3 2023 Net Income-$22.10M-$22.10MN/M vs Q3 2023 EPS Diluted-$0.24-$0.24N/M vs Q3 2023 Gross Profit$149,800,000— Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Operating Cash Flowderived$700,000N/M Margins · derivedGross margin70.2%
Operating margin-9.4%+21.9 pt vs Q3 2023
Net margin-10.4%+21.6 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 8, 2024 · 39 d after period end